Free shipping on all orders over $ 500

JAK Janus Kinase

Cat.No.  Name Information
M3030 S-Ruxolitinib S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M1820 Tofacitinib Tofacitinib (formerly tasocitinib, CP-690550) is a novel Janus Kinase 3 (JAK-3) kinase inhibitor with an IC50 value estimated at 0.2 μM.
M1660 AZ 960 AZ 960 is a novel and specific inhibitor of the JAK2 kinase with a Ki of 0.45nM in vitro.
M1646 AG490 AG490 (Tyrphostin AG490) is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).
M1733 TG101348 TG101348 is a selective small-molecule Janus kinase 2 (JAK2) inhibitor with IC50 of 3 nM.
M1787 INCB18424 INCB18424 is a potent inhibitor of both JAK1 and JAK2 with selectivity versus JAK3 and TYK2 (IC50 values of 2.7, 4.5, 332, and 19 nM, respectively, in biochemical assays).
M5944 Ruxolitinib phosphate Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
M3616 Tofacitinib citrate Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.
M2346 Filgotinib Filgotinib (GLPG0634) is the first selective inhibitor of JAK1 and JAK2 with IC50 of 10nM and 28nM respectively.
M2044 AZD1480 AZD1480 is a novel small-molecule inhibitor of JAK1/2 with IC50 of 1.3 nM and 0.26 nM, respectively.
M1804 NVP-BSK805 dihydrochloride NVP-BSK805 dihydrochloride is a potent and selective quinoxaline JAK2 inhibitor with IC50 values of 0.48, 0.56 and 0.58 nM for JAK2 JH1, FL JAK V617F and FL JAK2 wt respectively.
M1754 WP1130 Degrasyn (WP1130) is a small molecular deubiquitinase (DUB) inhibitor and suppresses JAK-Stat signaling pathway.
M1700 Momelotinib (CYT387) Momelotinib (CYT387) is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively.
M40851 SDC-1802 SDC-1802 is a JAK1/TYK2 inhibitor that can be used in studies related to systemic lupus erythematosus.
M40850 OST-246 OST-246 is an inhibitor of JAK3, MAP3K11, and TYK2 for studies related to autoimmune diseases and inflammation.
M40849 NDI-031232 NDI-031232 is a TYK2 inhibitor.
M40848 NDI-031301 NDI-031301 is a TYK2 inhibitor.
M40847 NDI-031407 NDI-031407 is a TYK2 inhibitor for studies related to endocrine metabolic diseases and psoriasis.
M40846 A2A-I-01 A2A-I-01 is a TYK2 inhibitor that can be used in studies related to autoimmune diseases.
M40840 GLPG3121 GLPG3121 is a JAK1/TYK2 inhibitor that can be used in studies related to inflammation and psoriasis.
M40839 SDC-1801 SDC-1801 is a JAK1/TYK2 inhibitor that can be used in studies related to inflammatory bowel disease, multiple sclerosis, and psoriasis.
M40837 BGB-23339 BGB-23339 is a highly selective TYK2 variant inhibitor for studies related to autoimmune diseases.
M40836 ABBV-712 ABBV-712 is a TYK2 inhibitor that can be used in studies related to psoriasis.
M40835 OST-122 OST-122 is a JAK3/SYK2/ARK5 multi-target inhibitor for ulcerative colitis related studies.
M40834 VTX-958 VTX-958 is an allosteric TYK2 inhibitor that can be used in studies related to psoriasis.
M40833 GLPG3667 GLPG3667 is a selective tyrosine kinase 2 (TYK2) inhibitor for studies related to systemic lupus erythematosus and psoriasis.
M40831 ESK-001 ESK-001 is a highly selective and potentially first-in-class heterotrimeric tyrosine kinase 2 (TYK2) inhibitor for studies related to systemic lupus erythematosus (SLE).
M40829 BMS-986322 BMS-986322 is a TYK2 inhibitor that may be used in studies related to psoriasis.
M40753 Ritlecitinib tosylate Ritlecitinib tosylate is a first-in-class, orally active, dual covalent inhibitor of tyrosine kinases in the JAK3 and TEC families. The IC50 for JAK3 is 33.1 nM and there is no activity against JAK1, JAK2 and TYK2.
M30102 Coumermycin A1  Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.




Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.